Advaxis
Clinical-stage biotechnology company developing immunotherapies for cancer and infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 59 % | (5 %) | (80 %) | (98 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (752 %) | (798 %) | (1114 %) | (5385 %) | (275915 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (762 %) | (813 %) | (1148 %) | (5493 %) | (369785 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 618 % | 604 % | 854 % | 4025 % | 185238 % |
Source: Company filings or news article
Related Content
Advaxis, Inc. (advaxis.com) is a clinical-stage biotechnology company specializing in the development and commercialization of innovative immunotherapies. These therapies are designed to treat various types of cancer by leveraging a unique platform technology. This platform uses live attenuated Listeria monocytogenes (Lm), a type of bacteria that has been bioengineered to produce specific proteins that help stimulate the body's immune response against cancer cells.
The company's primary focus is on creating antigen delivery products that can effectively target and treat cancers associated with the prostate (PSA), HER2, HPV, and other tumor-associated antigens. Advaxis's pipeline includes several promising programs such as the HOT Program for HER2-associated cancers, the NEO Program for personalized cancer treatments, and therapies for HPV-associated cancers.
Advaxis primarily serves patients battling various forms of cancer, offering them new hope through cutting-edge immunotherapy treatments. The company operates in the highly competitive biotechnology and pharmaceutical markets, where innovation and clinical efficacy are critical for success.
The business model of Advaxis revolves around the development and clinical testing of its proprietary immunotherapy products. Once these products demonstrate safety and efficacy in clinical trials, the company aims to commercialize them, either independently or through partnerships with larger pharmaceutical companies. Revenue is generated through product sales, licensing agreements, and potential milestone payments from partners.
In summary, Advaxis is at the forefront of cancer immunotherapy, utilizing a novel approach to harness the power of the immune system to fight cancer. The company's innovative platform and diverse pipeline position it well in the biotechnology market, offering significant potential for growth and impact in the field of cancer treatment.
Keywords: immunotherapy, biotechnology, cancer treatment, Listeria monocytogenes, antigen delivery, clinical trials, PSA, HER2, HPV, personalized medicine.